文献速递肿瘤 PET/CT骨显像与常规 SPECT

18F-DCFPyL与18F-PSMA-1007 PET/CT在240例前列腺癌患者中的配对比较:阅片者间一致性与可疑病灶检出率

Matched-Pair Comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions.
PubMed 文献 · J Nucl Med · 2021-02-05

本研究将120例连续接受18F-PSMA-1007扫描的患者与120例接受18F-DCFPyL扫描的患者进行配对,由2名阅片者按PSMA Reporting and Data System标准评估240例PET/CT。两种显像剂总体一致性良好,但18F-PSMA-1007在前列腺/前列腺窝可疑病灶检出率更高(尤其生化复发亚组),18F-DCFPyL在骨病灶阅片者间一致性更高且可疑骨病灶更少。

要点

  • 18F-PSMA-1007在前列腺或前列腺窝可疑病灶检出率高于18F-DCFPyL,生化复发亚组尤为明显
  • 两者检出可疑淋巴结能力相当,但18F-DCFPyL的阅片者间一致性更高
  • 18F-DCFPyL可疑骨病灶更少且骨病灶阅片者间一致性更高

核心结论

  • 18F-DCFPyL与18F-PSMA-1007之间存在临床相关差异,可能造成诊断困境,并可能影响PSMA靶向显像剂的选择。

研究设计与样本

  • 研究将120例连续接受18F-PSMA-1007扫描的患者与120例接受18F-DCFPyL扫描的患者进行配对,共240例PET/CT由2名阅片者按PSMA Reporting and Data System标准评估。

主要发现

  • 18F-PSMA-1007在前列腺或前列腺窝可疑病灶的检出患者比例更高,尤其在因生化复发而扫描的亚组中。
  • 18F-DCFPyL与18F-PSMA-1007检出可疑淋巴结的能力相当,但18F-DCFPyL的阅片者间一致性更高。
  • 18F-DCFPyL显示的可疑骨病灶更少,且骨病灶的阅片者间一致性更高。
  • 18F-PSMA-1007发现的大多数可疑病灶至少被判定为非转移性来源。

临床怎么用

  • 在前列腺癌PSMA PET/CT显像剂选择时,需考虑18F-DCFPyL与18F-PSMA-1007在前列腺/前列腺窝病灶检出和骨病灶判读一致性上的差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Over 20 different prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals for both imaging and therapy have been synthesized. Although variability in biodistribution and affinity for binding to the PSMA receptor is known to exist between different PSMA-targeting radiopharmaceuticals, little is known about the clinical implications of this variability. Therefore, this study analyzed differences in interreader agreement and detection rate between 2 regularly used 18F-labeled PSMA receptor-targeting radiopharmaceuticals: 18F-DCFPyL and 18F-PSMA-1007. Methods: One hundred twenty consecutive patients scanned with 18F-PSMA-1007 were match-paired with 120 patients scanned with 18F-DCFPyL. All 240 PET/CT scans were reviewed by 2 readers and scored according to the criteria of the PSMA Reporting and Data System. Interreader agreement and the detection rate for suspected lesions were scored for different anatomic locations such as the prostate, prostatic fossa, lymph nodes, and bone. Results: Great equality was found between 18F-DCFPyL and 18F-PSMA-1007; however, some clinically relevant and statistically significant differences were observed. 18F-PSMA-1007 detected suspected prostatic or prostatic fossa lesions in a higher proportion of patients and especially in the subcohort scanned for biochemical recurrence. 18F-DCFPyL and 18F-PSMA-1007 showed an equal ability to detect suspected lymph nodes, although interreader agreement for 18F-DCFPyL was higher. 18F-DCFPyL showed fewer equivocal skeletal lesions and higher interreader agreement on skeletal lesions. Most of the equivocal lesions found with 18F-PSMA-1007 at least were determined to be of nonmetastatic origin. Conclusion: Clinically relevant differences, which may account for diagnostic dilemmas, were observed between 18F-DCFPyL and 18F-PSMA-1007. Those findings encourage further studies, as they may have consequences for selection of the proper PSMA-targeting radiopharmaceutical.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Wondergem M, van der Zant FM, Broos WAM, et al. Matched-Pair Comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions. J Nucl Med. 2021. PMID: 33547211. doi:10.2967/jnumed.120.258574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。